Medication Comparison · Updated November 2026

Compounded Semaglutide vs Ozempic: What You Actually Need to Know

As of Nov 4, 2026, Novo Nordisk sells brand-name Ozempic pens self-pay for $349 per month (0.25 mg to 1 mg) or $499 (2 mg), after a $199 offer for new patients' first two fills, per NovoCare. Compounded semaglutide sells for less, but it is not FDA-approved, and since the shortage ended in 2025 the FDA no longer allows routine compounded copies. Here is what is different, what is the same, and what that means for you.

The Short Version

• Same active ingredient. Both contain semaglutide, the GLP-1 receptor agonist developed by Novo Nordisk.
• Compounded is NOT generic. There is no FDA-approved generic semaglutide. Compounded versions were made widely under FDA shortage rules, not through the generic approval process.
• The shortage is over. The FDA declared the semaglutide shortage resolved on February 21, 2025. Its grace periods for compounded copies ended in 2025 (May 22, 2025 for 503B outsourcing facilities).
• Price gap is smaller than it was. Ozempic self-pay is $349 to $499/mo on NovoCare. One compounded seller we track listed $116/mo. For people without insurance, the gap still matters.
• Oversight differs by pharmacy type. 503B outsourcing facilities are FDA-registered and follow cGMP. 503A pharmacies are mainly state-regulated. Neither makes the product FDA-approved.
• Clinical trial data exists only for the brand-name product. The 14.9% weight loss from the STEP trials was measured with Novo Nordisk’s manufactured semaglutide, not compounded versions.
• The FDA has issued warnings about compounded and counterfeit GLP-1 products, and reports 990 adverse event reports for compounded semaglutide as of May 31, 2026.

Quick Comparison Table

What Compounded Semaglutide Actually Is

Compounded semaglutide is not a generic. There is no FDA-approved generic version of semaglutide. That is a common misconception worth clearing up immediately.

Here is what it actually is: licensed compounding pharmacies buy the semaglutide active ingredient and formulate it into an injectable medication, often in bacteriostatic water and sometimes with added ingredients.

Compounding is governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. While semaglutide was on the FDA shortage list, compounders were allowed to make copies to fill the gap. The FDA declared that shortage resolved on February 21, 2025. After that, 503A pharmacies may not regularly compound drugs that are essentially copies of a commercially available product, and 503B outsourcing facilities may not make drugs that are essentially a copy of an approved drug. A compounded version is still allowed when a prescriber documents a patient-specific need, such as an allergy to an ingredient in the brand product.

The critical distinction from a generic: A generic drug goes through the FDA’s Abbreviated New Drug Application (ANDA) process, where the FDA reviews whether it matches the brand product. Compounded medications do not. The FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed.

503A vs 503B Pharmacies: This Matters

Not all compounding pharmacies operate under the same rules. Here is how the two types differ.

503B Outsourcing Facilities

• Registered with the FDA and subject to FDA inspection
• Must follow current Good Manufacturing Practices (cGMP), the same manufacturing standards that apply to traditional pharmaceutical companies
• Can produce larger batches without individual prescriptions, but may not make copies of approved drugs that are not in shortage
• Must report adverse events to the FDA
• Quality testing required for potency, sterility, and purity

503B outsourcing facilities face federal registration, inspection, current good manufacturing practice, adverse-event reporting, and other requirements that differ from the 503A framework. That does not make a compounded product FDA-approved or establish that it is equivalent to a brand-name drug. The relevant question is whether a licensed prescriber has identified a patient-specific need and whether the facility and product meet applicable requirements.

503A Pharmacies

• State-regulated, not directly FDA-regulated (though the FDA can intervene)
• Each prescription is compounded for an individual patient (cannot batch-produce)
• No cGMP requirement, though many follow their own quality protocols
• Less standardized testing for potency and sterility
• Quality varies significantly from pharmacy to pharmacy

503A pharmacies can produce good products. But the regulatory framework provides less assurance, and you are relying more heavily on the individual pharmacy’s internal practices.

What this means for you: With the shortage over, the bigger question is not 503A vs 503B but whether a compounded product is being made lawfully for you at all. Ask your prescriber why a compounded version is medically necessary in your case.

The Safety Question

This is the section everyone wants to get to. Is compounded semaglutide safe?

The honest answer: it depends on the source.

What the FDA Has Said

The FDA has issued multiple warnings about compounded GLP-1 products. Their concerns include:

• Substandard products with incorrect potency (too much or too little active ingredient)
• Sterility failures leading to contaminated injectables
• Salt forms. The FDA says semaglutide sodium and semaglutide acetate are different active ingredients and that it is not aware of any lawful basis for using them in compounding
• Counterfeit and fraudulent products sold online, including labels naming compounding pharmacies that do not exist
• Dosing errors, some leading to hospitalization, when patients measured and injected the wrong amount from a vial

The FDA has also sent warning letters to compounders and telehealth sellers over GLP-1 products.

What This Means in Practice

The FDA warnings are real and should not be dismissed. Risk depends heavily on the source, and on whether the product is lawful at all.

Lower risk: A product from a state-licensed pharmacy or FDA-registered 503B outsourcing facility that can show batch testing for potency, sterility and endotoxins, prescribed for a documented patient-specific need.

Higher risk: Anything from an online source without clear pharmacy credentials, any salt form (sodium or acetate), or any product that ships without a valid prescription. Avoid these.

Clinical Trial Data

All published clinical trial data for semaglutide (the STEP trials, SUSTAIN trials, SELECT trial) used Novo Nordisk’s manufactured product. No independent clinical trials have been conducted on compounded semaglutide. This means the 14.9% weight loss figure, the cardiovascular benefits, and the safety profile data apply specifically to the brand-name drug.

Does compounded semaglutide produce weight loss? There are anecdotal reports that it does, but the formal evidence base applies only to the brand product, and a compounded product’s real strength depends on the pharmacy.

Cost Comparison

On these listed prices, the gap is roughly $2,800 to $4,600 a year, far smaller than before Novo Nordisk cut its self-pay prices. Our compounded vs brand guide covers the trade-offs in more depth.

The flip side: If your commercial insurance covers Ozempic for type 2 diabetes, NovoCare’s savings card can bring it to as little as $25 a month for up to 3 months. At that price, brand-name Ozempic is cheaper than compounded semaglutide and comes with FDA-approved manufacturing.

If you want semaglutide for weight loss, the FDA-approved product is Wegovy, which NovoCare sells self-pay from $149/mo for the lowest-dose pill and $349/mo for the standard pen.

For a full comparison of all provider pricing, see our cheapest GLP-1 online guide.

Dosing Differences

Ozempic comes in a pre-filled injection pen with precise dose selection. You click to your dose, inject, and you are done. The pen handles the measuring.

Compounded semaglutide typically comes in a multi-dose vial. You draw up the correct amount with a syringe. This requires you (or your provider) to calculate the volume needed based on the concentration of the solution.

This is a practical difference that matters. Drawing from a vial is more error-prone than using a pre-filled pen. If the concentration of your compounded solution is 2 mg/mL and you need 0.5 mg, you draw 0.25 mL. Get the math wrong, and you are injecting the wrong dose. The FDA has received reports of hospitalizations linked to these dosing errors. Never convert doses yourself. Use the exact volume your prescriber and pharmacist give you, and call them if anything is unclear.

Some telehealth providers now offer compounded semaglutide in pre-filled syringes, which reduces the dosing error risk. If you are not comfortable with vial-and-syringe dosing, ask your provider about pre-filled options.

The Regulatory Situation (2026)

The legality of compounded semaglutide depended on the FDA’s shortage designation. Here is the timeline from the FDA:

• February 21, 2025: The FDA declared the semaglutide shortage resolved.
• April 24, 2025: A court denied a challenge to that decision, and the 503A grace period ended.
• May 22, 2025: The 503B grace period for outsourcing facilities ended.
• As of the FDA’s April 2026 update: semaglutide is not on the FDA drug shortage list or the 503B bulks list.

What this means for patients: some telehealth companies still sell compounded semaglutide, but routine copies of an approved drug are no longer allowed, and supply could be disrupted by enforcement action.

If you start on compounded semaglutide, have a backup plan. Know what your insurance covers for brand-name options, and understand the pricing for Wegovy (the FDA-approved weight loss version of semaglutide) in case compounded availability changes.

Choose Brand-Name Ozempic If…

• Your insurance covers it. If Ozempic is on your formulary for T2D, the copay may be cheaper than compounded semaglutide.
• You have type 2 diabetes. Ozempic is FDA-approved for T2D with years of clinical trial data behind it.
• You want weight loss. Wegovy is the FDA-approved semaglutide for weight management.
• You want FDA-approved manufacturing. Approved products are reviewed by the FDA for safety, effectiveness and quality.
• You prefer the convenience of a pre-filled pen. No measuring, no syringes, less room for dosing error.
• You value the clinical trial data. The STEP, SUSTAIN, and SELECT results apply specifically to the brand product.

When Compounded Semaglutide Might Come Up

• Your prescriber documents a patient-specific need. For example, an allergy to an ingredient in the brand product. This is the main lawful basis now that the shortage is over.
• You have compared the current self-pay prices first. Ozempic, Wegovy pens and the Wegovy pill now start at $149 to $349/mo on NovoCare, which narrows the savings.
• You can confirm the pharmacy. State-licensed or FDA-registered, with batch testing, and no salt forms.
• You understand the trade-offs. No formal clinical trial data on the compounded product, variable quality depending on source, and an uncertain regulatory future.

How to Evaluate a Compounded Semaglutide Provider

If you decide to go the compounded route, here is what to check:

1. Ask which pharmacy fills it. Is it a 503B outsourcing facility or a 503A pharmacy, and is it licensed in your state?
2. Request certificates of analysis (COA). Reputable providers can share batch testing results for potency and sterility.
3. Verify the prescription requirement. Any legitimate provider requires a prescription from a licensed prescriber. If someone offers semaglutide without a prescription, walk away.
4. Check the concentration and salt form. The FDA says semaglutide sodium and acetate salt forms have no lawful basis for compounding. If the label lists a salt form, do not use it.
5. Look for ongoing clinical support. You want dose adjustments, check-ins, and a prescriber you can reach. Avoid “ship and forget” operations.

We review telehealth providers at clearmetabolic.com/reviews/.

Frequently Asked Questions

Is compounded semaglutide the same as generic Ozempic?

No. There is no FDA-approved generic Ozempic. Compounded semaglutide is produced by compounding pharmacies using the raw semaglutide active ingredient. It has not gone through the FDA’s generic drug approval process (ANDA), which requires proof of bioequivalence. Compounded semaglutide was widely available under a separate legal framework tied to the FDA’s drug shortage policy, and that shortage ended in February 2025.

How do I know if my compounded semaglutide is real?

Ask your provider about the compounding pharmacy. Look for: (1) a state license or FDA registration as a 503B outsourcing facility, (2) certificates of analysis showing potency testing for each batch, (3) sterility testing documentation, and (4) no salt forms on the label. If your provider cannot or will not share this information, consider switching to one that can.

Will I get the same weight loss on compounded semaglutide?

There is no clinical trial data comparing compounded semaglutide to Ozempic. The formal evidence (14.9% weight loss from the STEP 1 trial) applies only to Novo Nordisk’s manufactured product.

What happens if the FDA shuts down compounded semaglutide?

If compounded semaglutide becomes unavailable to you, your options include: (1) brand-name Ozempic or Wegovy, now sold self-pay from $149/mo (Wegovy pill) or $349/mo (pens), (2) other FDA-approved drugs such as Zepbound or Foundayo, or (3) working with your prescriber on other approaches. Compounded tirzepatide faces the same legal limits, since its shortage also ended. Do not stop or switch medications without talking to your prescriber. This is why having a backup plan matters.

Can I use compounded semaglutide with my insurance?

Generally no. Insurers rarely cover compounded GLP-1s. If your insurance covers Ozempic (for T2D) or Wegovy (for weight management), those brand-name products are often cheaper than compounded semaglutide after your copay. Compounded semaglutide is a self-pay option.

Last updated: November 4, 2026. Pricing and availability may change. This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

What we checked

This AI-assisted public-source desk check reviewed FDA statements on compounded GLP-1 policy and safety, NovoCare’s Ozempic and Wegovy self-pay and savings pages, and MEDVi’s public pricing page on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.